Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Medtronic
AstraZeneca
Moodys
Harvard Business School

Last Updated: November 15, 2019

DrugPatentWatch Database Preview

Litigation Details for Gilead Sciences Inc. v. Mylan Pharmaceuticals Inc. (D. Del. 2016)

See Plans and Pricing

« Back to Dashboard

Gilead Sciences Inc. v. Mylan Pharmaceuticals Inc. (D. Del. 2016)

Docket   Start Trial Date Filed 2016-03-25
Court District Court, D. Delaware Date Terminated 2018-07-24
Cause 35:271 Patent Infringement Assigned To Kent A. Jordan
Jury Demand None Referred To
Parties GILEAD SCIENCES INC.; MYLAN PHARMACEUTICALS INC.
Patents 8,148,374
Attorneys Adam K. Mortara; Aden M. Allen; AnnaMartina Tyreus Hufnal; Douglas Edward McCann; Grace J. Pak; J. Scott McBride; Jack B. Blumenfeld; James B. Heaton; James B. Heaton , III; James G. Gorman , III; James Michael Lennon; Jeremy A. Tigan; Nevin M. Gewertz; Nicole W. Stafford; Olin Ray Hebert , III.; Rebecca T. Horwitz; Robert A. Delafield , II; Robert M. Vrana; Sami Sedghani; Susan E. Morrison; Susan Morrison Coletti
Firms Devlin Law Firm LLC; Morris, Nichols, Arsht & Tunnell; Young, Conaway, Stargatt & Taylor LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Gilead Sciences Inc. v. Mylan Pharmaceuticals Inc.
The small molecule drugs covered by the patent cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Gilead Sciences Inc. v. Mylan Pharmaceuticals Inc. (D. Del. 2016)

Date Filed Document No. Description Snippet Link To Document
2016-03-25 4 Patent/Trademark Report to Commissioner the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,148,374 B2;. (dmp, ) (Entered…2016 24 July 2018 1:16-cv-00192 830 Patent None District Court, D. Delaware External link to document
2017-09-12 79 Notice (Other) M.D. Fortunak, Ph.D. on Invalidity of U.S. Patent No. 8,148,374 and supporting materials by Mylan Pharmaceuticals…2016 24 July 2018 1:16-cv-00192 830 Patent None District Court, D. Delaware External link to document
2017-09-29 80 Notice of Service Fortunak, Ph.D. Regarding Invalidity of U.S. Patent No. 8,148,374 filed by Mylan Pharmaceuticals Inc..(Lennon…2016 24 July 2018 1:16-cv-00192 830 Patent None District Court, D. Delaware External link to document
2017-11-07 82 Notice (Other) M.D. Fortunak, Ph.D. on Invalidity of U.S. Patent No. 8,148,374 by Mylan Pharmaceuticals Inc. (Lennon, James…2016 24 July 2018 1:16-cv-00192 830 Patent None District Court, D. Delaware External link to document
2018-07-24 97 Patent/Trademark Report to Commissioner the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,148,374 B2. (rwc) (Entered:…2016 24 July 2018 1:16-cv-00192 830 Patent None District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Baxter
McKesson
Express Scripts
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.